These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 9060528

  • 1. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
    Blanke CD, Kasimis B, Schein P, Capizzi R, Kurman M.
    J Clin Oncol; 1997 Mar; 15(3):915-20. PubMed ID: 9060528
    [Abstract] [Full Text] [Related]

  • 2. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
    Conti JA, Kemeny N, Seiter K, Goker E, Tong W, André M, Ragusa K, Bertino JR.
    J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
    [Abstract] [Full Text] [Related]

  • 3. Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.
    Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Tixi LM, Bolli EA, Rosso R, Mammoliti S, Rollandi GA, Bertoglio S.
    Clin Cancer Res; 1995 Sep; 1(9):955-60. PubMed ID: 9816066
    [Abstract] [Full Text] [Related]

  • 4. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
    Szelényi H, Hohenberger P, Lochs H, Haboubi N, Berdel WE, Thiel E, Kreuser ED.
    Oncology; 2000 May; 58(4):273-9. PubMed ID: 10838491
    [Abstract] [Full Text] [Related]

  • 5. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-Montefiore D.
    Br J Cancer; 2007 Feb 26; 96(4):551-8. PubMed ID: 17262086
    [Abstract] [Full Text] [Related]

  • 6. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers.
    Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, Chang KJ, Lee PH, Chen YC.
    Anticancer Res; 1997 Feb 26; 17(5B):3867-71. PubMed ID: 9427794
    [Abstract] [Full Text] [Related]

  • 7. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, Michaelis J, Meyer zum Büschenfelde KH, Knuth A.
    J Clin Oncol; 1996 Aug 26; 14(8):2274-9. PubMed ID: 8708717
    [Abstract] [Full Text] [Related]

  • 8. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.
    Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E, Fountzilas G.
    J Clin Oncol; 1996 Oct 26; 14(10):2682-7. PubMed ID: 8874327
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H.
    Jpn J Clin Oncol; 2007 Sep 26; 37(9):686-91. PubMed ID: 17720736
    [Abstract] [Full Text] [Related]

  • 10. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J, González Barón M, García-Girón C, Espinosa E, García-Alfonso P, Belón J, Blanco E, Garrido P, Ordónez A, Gómez-Navarro J, Zamora P.
    Cancer; 1996 Jul 15; 78(2):211-6. PubMed ID: 8673994
    [Abstract] [Full Text] [Related]

  • 11. Chemo-biotherapy with 5-fluorouracil, leucovorin, and alpha interferon in metastatic carcinoma of the colon--a Cancer Biotherapy Research Group [CBRG] phase II study.
    Soori GS, Oldham RK, Dobbs TW, Bury MJ, Church CK, DePriest C.
    Cancer Biother Radiopharm; 2000 Apr 15; 15(2):175-83. PubMed ID: 10803323
    [Abstract] [Full Text] [Related]

  • 12. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience.
    Wang WS, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Yen CC, Fan FS, Hsieh RK.
    Jpn J Clin Oncol; 1998 Jan 15; 28(1):16-9. PubMed ID: 9491136
    [Abstract] [Full Text] [Related]

  • 13. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
    Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich LJ, Mittelman A.
    J Clin Oncol; 1987 Oct 15; 5(10):1559-65. PubMed ID: 2443619
    [Abstract] [Full Text] [Related]

  • 14. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y, Ohtsu A, Boku N, Miyata Y, Shimada Y, Doi T, Muro K, Muto M, Hamaguchi T, Mera K, Yano T, Tanigawara Y, Shirao K.
    Jpn J Clin Oncol; 2006 Apr 15; 36(4):218-23. PubMed ID: 16684860
    [Abstract] [Full Text] [Related]

  • 15. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
    Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP.
    J Clin Oncol; 1996 Nov 15; 14(11):2959-67. PubMed ID: 8918493
    [Abstract] [Full Text] [Related]

  • 16. A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.
    Haas NB, Schilder RJ, Nash S, Weiner LM, Catalano RC, Ozols RF, O'Dwyer PJ.
    Invest New Drugs; 1995 Nov 15; 13(3):229-33. PubMed ID: 8729951
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G, Tucci A, Rinaldi A, Colarusso D, Pizza C, Reggiardo G, Manzione L.
    Oncology; 2004 Nov 15; 66(5):371-8. PubMed ID: 15331924
    [Abstract] [Full Text] [Related]

  • 18. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, Dimitrakopoulos A, Karadima D, Rokana S, Papalambros E, Papastratis G, Margaris H, Tsipras H, Polyzos A.
    Cancer Chemother Pharmacol; 2003 Dec 15; 52(6):514-9. PubMed ID: 14504920
    [Abstract] [Full Text] [Related]

  • 19. Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience.
    Maroun JA, Cripps C, Goel R, Dahrouge S, Boisvert D.
    Am J Clin Oncol; 1997 Aug 15; 20(4):387-92. PubMed ID: 9256896
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
    Ji SH, Park YS, Lee J, Lim DH, Park BB, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K.
    Jpn J Clin Oncol; 2005 Apr 15; 35(4):214-7. PubMed ID: 15845571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.